A PhaseII trial of oral etopocide and iv irinotecan for patients with platinum resistant and taxane pretreated ovarian cancer(JCOG0503)
- Conditions
- platinum resistant and taxane pretreated ovarian cancer
- Registration Number
- JPRN-UMIN000001837
- Lead Sponsor
- Japan Clinical Oncology Group(JCOG)
- Brief Summary
See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 60
Not provided
1. Patients with a concomitant or prior invasive malignancy (except intramucosal malignancy which are curable with local therapy) who have had any evidence of the disease within the last 5 years 2. Patients who cannot undergo treatment due to the past history of mental disorder or the central nerve disorder 3. Women during pregnancy or breast-feeding 4. Patients who have been treated with the systemic steroids medication 5. Patients with active infection 6. Patients with uncontrollable hypertension 7. Patients with uncontrollable diabetes 8. Patients with history of myocardial infarction, unstable angina, or heart failure within six months 9. Patients with bowel obstruction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method adverse event, progression free survival, overall survival